Preclinical experiments in explant cultures of human and murine (Hesx1Cre/+; Ctnnb1lox(ex3)/+ mouse model) ACP tumours have shown that treatment with Trametinib, a clinically approved MEK inhibitor, can reduce proliferation and induce apoptosis in ACP tumour cells [22]. This evidence concerns the gene MAP2K7 and neoplasm.